Table 2 |
||||
|
PSA, PSAP, and Hormone Receptor Expression in MBC, FBC, and Gynecomastia. |
||||
|
Marker |
Gynecomastia |
MBC |
FBC |
P-value (MBC vs FBC) |
|
|
||||
|
PSA |
0/5 (0%) |
1/30 (3.3%) |
2/54 (3.7%) |
1.00 |
|
|
||||
|
PSAP |
0/5 (0%) |
0/29 (0%) |
0/54 (0%) |
1.00 |
|
|
||||
|
AR |
4/5 (80%) |
20/27 (74.1%) |
38/56 (67.9%) |
0.62 |
|
|
||||
|
ER |
6/6 (100%) |
23/27 (85.2%) |
37/54 (68.5%) |
0.18 |
|
|
||||
|
PR |
5/5 (100%) |
14/27 (51.9%) |
27/56 (48.2%) |
0.82 |
|
|
||||
|
MBC - male breast carcinoma; FBC - female breast carcinoma; PSA - prostate specific antigen; PSAP - prostate specific acid phosphatase; AR - androgen receptor; ER - estrogen receptor; PR - progesterone receptor. |
||||
|
Kraus et al. Diagnostic Pathology 2010 5:63 doi:10.1186/1746-1596-5-63 |
||||
